Tsemperouli M, Cheppali S, Molina F, Chetrit D, Landajuela A, Toomre D
bioRxiv. 2024; .
PMID: 39314345
PMC: 11419119.
DOI: 10.1101/2024.09.12.612660.
Wang Y, Ye Z, Lou X, Xu J, Jing D, Zhou C
Hum Cell. 2024; 37(5):1522-1534.
PMID: 39078546
DOI: 10.1007/s13577-024-01107-5.
Herrera-Martinez A, Fuentes-Fayos A, Sanchez-Sanchez R, Montero A, Sarmento-Cabral A, Galvez-Moreno M
Int J Mol Sci. 2024; 25(4).
PMID: 38396713
PMC: 10888480.
DOI: 10.3390/ijms25042036.
Scheicher N, Berchtold S, Beil J, Smirnow I, Schenk A, Lauer U
Cancers (Basel). 2024; 16(3).
PMID: 38339240
PMC: 10854751.
DOI: 10.3390/cancers16030488.
Vitale G, Carra S, Alessi Y, Campolo F, Pandozzi C, Zanata I
Int J Mol Sci. 2023; 24(4).
PMID: 36835022
PMC: 9961914.
DOI: 10.3390/ijms24043610.
Recent progress of experimental model in pancreatic neuroendocrine tumors: drawbacks and challenges.
Wang Y, Wang F, Qin Y, Lou X, Ye Z, Zhang W
Endocrine. 2023; 80(2):266-282.
PMID: 36648608
DOI: 10.1007/s12020-023-03299-6.
Co-Expression of Adaptor Protein FAM159B with Different Markers for Neuroendocrine Cells: An Immunocytochemical and Immunohistochemical Study.
Beyer A, Kaemmerer D, Sanger J, Lupp A
Int J Mol Sci. 2022; 23(21).
PMID: 36362289
PMC: 9655893.
DOI: 10.3390/ijms232113503.
The link between menin and pleiotrophin in the tumor biology of pancreatic neuroendocrine neoplasms.
He L, Boulant S, Stanifer M, Guo C, Niessen A, Chen M
Cancer Sci. 2022; 113(5):1575-1586.
PMID: 35179814
PMC: 9128182.
DOI: 10.1111/cas.15301.
Role of miR-24 in Multiple Endocrine Neoplasia Type 1: A Potential Target for Molecular Therapy.
Marini F, Brandi M
Int J Mol Sci. 2021; 22(14).
PMID: 34298972
PMC: 8306915.
DOI: 10.3390/ijms22147352.
Chemotherapy-Induced Upregulation of Somatostatin Receptor-2 Increases the Uptake and Efficacy of Lu-DOTA-Octreotate in Neuroendocrine Tumor Cells.
Shah R, Merlin M, Adant S, Zine-Eddine F, Beauregard J, Shah G
Cancers (Basel). 2021; 13(2).
PMID: 33435224
PMC: 7828052.
DOI: 10.3390/cancers13020232.
Oncolytic vaccinia virus GLV-1h68 exhibits profound antitumoral activities in cell lines originating from neuroendocrine neoplasms.
Kloker L, Berchtold S, Smirnow I, Beil J, Krieg A, Sipos B
BMC Cancer. 2020; 20(1):628.
PMID: 32631270
PMC: 7339398.
DOI: 10.1186/s12885-020-07121-8.
Enhancing the anti-tumour activity of Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP.
Cullinane C, Waldeck K, Kirby L, Rogers B, Eu P, Tothill R
Sci Rep. 2020; 10(1):10196.
PMID: 32576907
PMC: 7311440.
DOI: 10.1038/s41598-020-67199-9.
Loss of copy of MIR1-2 increases CDK4 expression in ileal neuroendocrine tumors.
Contractor T, Harris C
Oncogenesis. 2020; 9(3):37.
PMID: 32198354
PMC: 7083839.
DOI: 10.1038/s41389-020-0221-4.
Overexpression of somatostatin receptor type 2 in neuroendocrine tumors for improved Ga68-DOTATATE imaging and treatment.
Guenter R, Aweda T, Carmona Matos D, Jang S, Whitt J, Cheng Y
Surgery. 2019; 167(1):189-196.
PMID: 31629542
PMC: 8422841.
DOI: 10.1016/j.surg.2019.05.092.
Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms.
Gatto F, Barbieri F, Arvigo M, Thellung S, Amaru J, Albertelli M
Int J Mol Sci. 2019; 20(16).
PMID: 31412614
PMC: 6720449.
DOI: 10.3390/ijms20163940.
Pharmacological Inhibition of Class IIA HDACs by LMK-235 in Pancreatic Neuroendocrine Tumor Cells.
Wanek J, Gaisberger M, Beyreis M, Mayr C, Helm K, Primavesi F
Int J Mol Sci. 2018; 19(10).
PMID: 30321986
PMC: 6213165.
DOI: 10.3390/ijms19103128.
Histopathological, immunohistochemical, genetic and molecular markers of neuroendocrine neoplasms.
Kyriakopoulos G, Mavroeidi V, Chatzellis E, Kaltsas G, Alexandraki K
Ann Transl Med. 2018; 6(12):252.
PMID: 30069454
PMC: 6046289.
DOI: 10.21037/atm.2018.06.27.
Potentiation of Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor.
Purohit N, Shah R, Adant S, Hoepfner M, Shah G, Beauregard J
Oncotarget. 2018; 9(37):24693-24706.
PMID: 29872498
PMC: 5973847.
DOI: 10.18632/oncotarget.25266.
Epidrug-induced upregulation of functional somatostatin type 2 receptors in human pancreatic neuroendocrine tumor cells.
Veenstra M, Van Koetsveld P, Dogan F, Farrell W, Feelders R, Lamberts S
Oncotarget. 2018; 9(19):14791-14802.
PMID: 29599907
PMC: 5871078.
DOI: 10.18632/oncotarget.9462.
IGF-IEc expression is increased in secondary compared to primary foci in neuroendocrine neoplasms.
Alexandraki K, Philippou A, Boutzios G, Theohari I, Koutsilieris M, Delladetsima I
Oncotarget. 2017; 8(45):79003-79011.
PMID: 29108282
PMC: 5668015.
DOI: 10.18632/oncotarget.20743.
